‘BrainStorm’ Receives $1.1M Grant From Israel’s Chief Scientist

BrainStorm Cell Therapeutics, a developer of adult stem cell therapeutics targeting Central Nervous System (CNS) neurodegenerative diseases, announced today that the company received a grant of approximately $1.1 million from Israel’s Office of the Chief Scientist. The grant is awarded to towards the development of BrainStorm’s NurOwn therapy for the neurodegenerative disease ALS – also known as Lou Gehrig’s Disease – using adult stem cells. The treatment is currently under clinical trials in Israel, with interim results expected by July 2012.